Linda Garland, MD

Cancer Prevention and Control Program

Biography

Undergraduate Education

University of Texas at Austin Austin, Texas, Bachelor of Arts with High Honors, 1983, Special Honors in Psychology 
1979 -1983                            

Medical Education  

University of Texas Health Science Center at San Antonio, San Antonio, Texas 
8/1984 -5/1988                

Surgery Internship, Department of Surgery University of Texas Health Science Center at San Antonio, San Antonio, Texas 
7/1988 -6/1989                    

Internal Medicine Internship and Residency, Department of Internal Medicine, University of South Florida College of Medicine, Tampa, Florida              
7/1990 - 6/1993                                                   

Medical Oncology and Hematology Fellowship, Division of Medical Oncology and Hematology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida 
7/1993 – 6/1996                       

Employment 

7/1996 – 1/2000                            

Assistant Professor of Medicine, Thoracic Oncology Program, H. Lee Moffitt Cancer Center, University of South Florida College of Medicine, Tampa, Florida 

2/2000 – 6/2007                            

Assistant Professor of Medicine, Clinical Scholar Track,

Director, Clinical Research in Thoracic Oncology, University of Arizona Cancer Center, Division of Hematology/Oncology, Department of Medicine 

 7/2007 – 5/2018                            

Associate Professor of Medicine, Clinical Scholar Track 

Director, Clinical Research in Thoracic Oncology, University of Arizona Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of Arizona Health Sciences Center 

6/2018 – Present                    

Professor of Medicine, Clinical Scholar Track 

Director, Clinical Research in Thoracic Oncology 

University of Arizona Cancer Center, Division of Hematology/Oncology, Department of Medicine , University of Arizona Health Sciences Center 

Cancer Focus

-Lung cancer chemoprevention with repurposed drugs including arachidonic acid inhibitors and immune modulators, and incorporating novel non-invasive biomarkers of gene expression. 

-Lung cancer survivorship studies including lung cancer stigma, lung cancer outcomes by race/ethnicity, coping responses in the face of the COVID pandemic, tobacco cessation.

-Translation of a novel methylation signature discovered at the UACC for improving lung cancer diagnosis and treatment response.